Abstract:The massive loss of oligodendrocytes caused by various pathological factors is a basic feature of many demyelinating diseases of the central nervous system (CNS). Based on a variety of studies, it is now well established that impairment of oligodendrocyte precursor cells (OPCs) to differentiate and remyelinate axons is a vital event in the failed treatment of demyelinating diseases. Recent evidence suggests that Foxg1 is essential for the proliferation of certain precursors and inhibits premature neurogenesis during brain development. To date, very little attention has been paid to the role of Foxg1 in the proliferation and differentiation of OPCs in demyelinating diseases of the CNS. Here, for the first time, we examined the effects of Foxg1 on demyelination and remyelination in the brain using a cuprizone (CPZ)-induced mouse model. In this work, 7-week-old Foxg1 conditional knockout and wild-type (WT) mice were fed a diet containing 0.2% CPZ w/w for 5 weeks, after which CPZ was withdrawn to enable remyelination. Our results demonstrated that, compared with WT mice, Foxg1-knockout mice exhibited not only alleviated demyelination but also accelerated remyelination of the demyelinated corpus callosum. Furthermore, we found that Foxg1 knockout decreased the proliferation of OPCs and accelerated their differentiation into mature oligodendrocytes both in vivo and in vitro. Wnt signaling plays a critical role in development and in a variety of diseases. GSK-3β, a key regulatory kinase in the Wnt pathway, regulates the ability of β-catenin to enter nuclei, where it activates the expression of Wnt target genes. We then used SB216763, a selective inhibitor of GSK-3β activity, to further demonstrate the regulatory mechanism by which Foxg1 affects OPCs in vitro. The results showed that SB216763 clearly inhibited the expression of GSK-3β, which abolished the effect of the proliferation and differentiation of OPCs caused by the knockdown of Foxg1. These results suggest that Foxg1 is involved in the proliferation and differentiation of OPCs through the Wnt signaling pathway. The present experimental results are some of the first to suggest that Foxg1 is a new therapeutic target for the treatment of demyelinating diseases of the CNS.

PLP1-Targeting Antisense Oligonucleotides Improve FOXG1 Syndrome Mice

Conditional Deletion of Foxg1 Delayed Myelination during Early Postnatal Brain Development

Paving Therapeutic Avenues for FOXG1 Syndrome: Untangling Genotypes and Phenotypes from a Molecular Perspective

Case Report: FOXP1 Syndrome Caused by a De Novo Splicing Variant (c.1652+5 G>A) of the FOXP1 Gene.

The postnatal injection of AAV9-FOXG1 rescues corpus callosum agenesis and other brain deficits in the mouse model of FOXG1 syndrome

FOXG1 targets BMP repressors and cell cycle inhibitors in human neural progenitor cells

Identification of a de novo mutation of the FOXG1 gene and comprehensive analysis for molecular factors in Chinese FOXG1-related encephalopathies

FOXR1 regulates stress response pathways and is necessary for proper brain development

Foxg1 Regulates the Postnatal Development of Cortical Interneurons

Foxp2 loss of function increases striatal direct pathway inhibition via increased GABA release

Conditional Deletion of Foxg1 Alleviates Demyelination and Facilitates Remyelination Via the Wnt Signaling Pathway in Cuprizone-Induced Demyelinated Mice

Lethal lung hypoplasia and vascular defects in mice with conditional Foxf1 overexpression

Characterization of Human FOXN1 Mutations Uncovers both Loss- and Gain-of-Function Outcomes

Loss of Foxg1 Impairs the Development of Cortical SST-Interneurons Leading to Abnormal Emotional and Social Behaviors.

Reduced LYNX1 expression in transcriptome of human iPSC-derived neural progenitors modeling fragile X syndrome

Cell type specific roles of FOXP1 during early neocortical murine development

Impaired Interneuron Development after Foxg1 Disruption.

FOXG1 Drives Transcriptomic Networks to Specify Principal Neuron Subtypes During the Development of the Medial Pallium

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

Differential vulnerability of adult neurogenic niches to dosage of the neurodevelopmental-disorder linked gene Foxg1

Mitochondrial dysfunction and oxidative stress contribute to cognitive and motor impairment in FOXP1 syndrome